Eli Lilly (NYSE:LLY) announced Thursday that its diabetes therapy, Mounjaro (tirzepatide), succeeded in a late-stage trial ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

Several new weight loss drugs are undergoing trials in the UK. These drugs will work similarly to those already available but ...

Preliminary data from a large Phase 3 clinical trial is offering promising signs for a new anti-obesity drug. Called tirzepatide, the drug helped overweight and obese participants lose up to 22.5 ...

A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

Notably, 31.6% of patients receiving tirzepatide achieved at least 25% body weight loss (key secondary endpoint) compared with 16.1% of those taking semaglutide.

The twincretin tirzepatide produced jaw-dropping levels of weight loss in people with obesity and no diabetes compared with placebo in the SURMOUNT-1 pivotal trial with more than 2500 participants.

In 2022, a phase 3 randomized, controlled clinical trial demonstrated that tirzepatide led to a 20 percent reduction in body weight over 72 weeks.

For example, analysis of data from the SURPASS-3 trial by Viljoen et al. revealed that the median time to first achieve the HbA1c of 7.0% was 8.1 weeks for each dose of tirzepatide compared with ...

Two trials have now found tirzepatide, sold under the brand name Mounjaro as a diabetes treatment, to be effective for weight loss. It is likely to be approved later this year.

Eli Lilly's tirzepatide helped people lose up to 50 pounds, the sort of weight loss results only consistently seen with bariatric surgery. By Ed Cara Published May 6, 2022 | Comments (0) 𝕏 ...

Endocrinology > Obesity Tirzepatide Tops Semaglutide for Weight Loss in Head-to-Head Trial, Eli Lilly Says — Dual GLP-1/GIP drug yielded an average 47% greater relative weight loss compared to ...